ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference

06 Feb 2024
www.globenewswire.com
ONL Therapeutics to Present at 2024 BIO CEO & Investor Conference
ANN ARBOR, Mich., Feb. 06, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, president and chief executive officer, will present a corporate update at the BIO CEO & Investor Conference on Tuesday, February 27 at 2:30 PM ET. The conference is taking place February 26-27, 2024, at the New York Marriott Marquis in New York City.
Mr. Esposito will also be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so by contacting ONL’s company contact at the email below.
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, age-related macular degeneration and inherited retinal disease.
For more information about ONL Therapeutics, please visit www.onltherapeutics.com.


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.